DIMERCAPTOSUCCINIC ACID DMSA- dimercaptosuccinic acid injection, powder, lyophilized, for solution 
AnazaoHealth Corporation

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

DMSA (Dimercaptosuccinic acid)

Dear Medical Professional,

Per your order, we have compounded DMSA as a sterile freeze-dried mixture. The characteristics of this preparation are:

DESCRIPTION

AnazaoHealth supplies DMSA as a compounded kit for preparing Tc 99m DMSA. Each Reaction vial contains 1.1 mg meso-2, 3-dimercaptosuccinic acid, 0.2 mg tin as stannous chloride, and 0.7 mg ascorbic acid. The vial is back filled with inert gas and may contain a partial vacuum.

Each Acetate buffer vial contains 1.2 ml Sodium Acetate .25 N. pH 5.2 to 5.6.

LDO normal saline included for dilution of prepared kit, if required

CLINICAL PHARMACOLOGY

Technetium Tc 99m DMSA, when administered intravenously apparently binds to plasma proteins in the blood and collects in the renal cortex.

INDICATIONS AND USAGE

Technetium Tc 99m DMSA by intravenous administration is indicated as a static kidney imaging agent.

CONTRAINDICATIONS

There are no known contraindications.

DOSAGE AND ADMINISTRATION

Preparation of Technetium Tc 99m DMSA is done by the following aseptic procedure:

  1. Waterproof gloves should be worn during the preparation
  2. Snap off the plastic lid and place room temperature reaction vial in an appropriate lead shield.
  3. Swab the rubber closure of the vial with a germicide
  4. Inject as close to 1 cc as possible of sterile additive free sodium pertechnetate Tc 99m injection containing up to 1480 MBq (40 mCi) into the vial freshly eluded within 2 hours from a technetium generator. Be sure to maintain inert atmosphere in vial by introducing as little air as possible during reconstitution. NOTE: If sodium pertechnetate Tc 99m injection must be diluted, use  only Low Dissolved Oxygen (LDO)
  5. Secure the lead shield cover. Swirl the vial gently to mix contents and let stand for 15 minutes. Add 1 ml Acetate buffer at this time. (This will interfere with the tagging process if introduced any earlier). Buffer must be added (May be added up to 1 hour after Tc 99m)
  6. Examine vial contents; if the solution is not clear and free of particulate matter and discoloration on visual inspection, it should not be used
  7. Measure the radioactivity by a suitable calibration system and record prior to patient administration
  8. Buffered material should be used within 2 hours
  9. Appropriate quality control is recommended

Tagging Tips

Storage and Handling

Store the kit at 2°-8°C (36°-46°F) and protect from light

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Figure 1

ec657ecb-figure-01
DIMERCAPTOSUCCINIC ACID  DMSA
dimercaptosuccinic acid injection, powder, lyophilized, for solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:51808-211
Route of AdministrationINTRAVENOUS
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
2,3-DIMERCAPTOSUCCINIC ACID (UNII: 4S9JU7XF01) (2,3-DIMERCAPTOSUCCINIC ACID - UNII:4S9JU7XF01) 2,3-DIMERCAPTOSUCCINIC ACID1.1 mg
Inactive Ingredients
Ingredient NameStrength
STANNOUS CHLORIDE (UNII: 1BQV3749L5) 0.20 mg
ASCORBIC ACID (UNII: PQ6CK8PD0R) 0.7 mg
Product Characteristics
Color    Scoreno score
ShapeSize
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:51808-211-011 in 1 KIT
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other07/01/2012
Labeler - AnazaoHealth Corporation (011038762)
Establishment
NameAddressID/FEIBusiness Operations
AnazaoHealth Corporation011038762MANUFACTURE(51808-211)

Revised: 7/2012
Document Id: ec657ecb-6327-464c-8aab-6d61a0546b83
Set id: 5b11e596-3044-429b-9e48-33ba00946151
Version: 1
Effective Time: 20120701
 
AnazaoHealth Corporation